SPEAKING
image description

Clinically Speaking Newsletter:
May Issue

Issue 12: May 2025
Clinically-Driven Pharmacy Care Puts Patients First While Reducing Drug Spending

One-Year Anniversary Edition

Does your PBM leverage clinically-driven, evidence-based data to make the right medication therapy decisions that ensure the health and wellbeing of your members?

Does your PBM have a state-of-the-art population health engine that powers clinically-driven pharmacy care decisions? EmpiRx Health’s unique population health engine optimizes patient health and wellbeing while substantially reducing drug costs.

Does your PBM demonstrate every day that they put your needs and interests first, rather than prioritizing their own profits?

In Case You Missed It:

EmpiRx Health is Now a Member of Transparency-Rx

​​​​EmpiRx Health recently announced that we are now a member of Transparency-Rx, an industry coalition that represents a growing list of innovative PBM companies and other organizations dedicated to transforming the pharmacy care industry. Transparency-Rx advocates for healthcare policies that help to change drug pricing for the better while promoting improved patient health outcomes. To learn more about EmpiRx Health’s membership with Transparency-Rx read the full press release by clicking the button below.


​Impact of PBM Reform on HR Benefits Management

HRMorning, a leading HR publication, recently published an article on what HR/benefits executives should know about PBM reform. The article mentions AllyRx, EmpiRx Health’s newly launched national pharmacy care network. It also describes EmpiRx Health as a unique, emerging pharmacist-led PBM company that focuses on improving member health outcomes and reducing prescription drug costs.

Read the full article by clicking the button below.  ​​​​

Upcoming Events:

EmpiRx Health is excited to be exhibiting at SHRM in San Diego, June 29th to July 2nd. Stop by booth 921 to discuss how a pharmacist-led, clinically-driven PBM is the right choice for your members!

Featured Case Study

Patient: 63-year-old female
​​​Diagnosis: Osteoporosis
Population Health Management Engine Identified: A new therapy available with lower-cost alternatives.

• Our clinical pharmacists discussed clinically appropriate alternatives with the prescriber for a high-cost prescription injection, Forteo, that the patient was prescribed.

• The alternative was safe, less costly, and in tablet form for the patient and plan.

• The patient is stable and doing well on the recommended alternative, Alendronate Sodium tablets.

Annual Plan Savings: $41,608